onglyza 5mg tablets
astrazeneca uk ltd - saxagliptin hydrochloride - tablet - 5mg
onglyza 2.5mg tablets
astrazeneca uk ltd - saxagliptin hydrochloride - tablet - 2.5mg
onglyza tablets 2.5 mg
astrazeneca singapore pte ltd - saxagliptin hydrochloride (anhydrous) 2.79 mg eqv saxagliptin - tablet, film coated - 2.5 mg - saxagliptin hydrochloride (anhydrous) 2.79 mg eqv saxagliptin 2.5 mg
onglyza tablets 5 mg
astrazeneca singapore pte ltd - saxagliptin hydrochloride (anhydrous) 5.58 mg eqv saxagliptin - tablet, film coated - 5 mg - saxagliptin hydrochloride (anhydrous) 5.58 mg eqv saxagliptin 5 mg
qtern
astrazeneca (israel) ltd - dapagliflozin as propanediol; saxagliptin as hydrochloride monohydrate - film coated tablets - dapagliflozin as propanediol 10 mg; saxagliptin as hydrochloride monohydrate 5 mg - saxagliptin and dapagliflozin - qtern, fixed dose combination of saxagliptin and dapagliflozin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus:- to improve glycaemic control when metformin and/or sulphonylurea (su) and one of the monocomponents of qtern do not provide adequate glycaemic control,- when already being treated with the free combination of dapagliflozin and saxagliptin.
qtern
astrazeneca (israel) ltd - dapagliflozin as propanediol; saxagliptin as hydrochloride monohydrate - film coated tablets - dapagliflozin as propanediol 10 mg; saxagliptin as hydrochloride monohydrate 5 mg - saxagliptin and dapagliflozin - qtern, fixed dose combination of saxagliptin and dapagliflozin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus:- to improve glycaemic control when metformin and/or sulphonylurea (su) and one of the monocomponents of qtern do not provide adequate glycaemic control,- when already being treated with the free combination of dapagliflozin and saxagliptin.
qtern
astrazeneca (israel) ltd - dapagliflozin as propanediol; saxagliptin as hydrochloride monohydrate - film coated tablets - dapagliflozin as propanediol 10 mg; saxagliptin as hydrochloride monohydrate 5 mg - saxagliptin and dapagliflozin - qtern, fixed dose combination of saxagliptin and dapagliflozin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus:- to improve glycaemic control when metformin and/or sulphonylurea (su) and one of the monocomponents of qtern do not provide adequate glycaemic control,- when already being treated with the free combination of dapagliflozin and saxagliptin.
qtern
astrazeneca (israel) ltd - dapagliflozin as propanediol; saxagliptin as hydrochloride monohydrate - film coated tablets - dapagliflozin as propanediol 10 mg; saxagliptin as hydrochloride monohydrate 5 mg - saxagliptin and dapagliflozin - qtern, fixed dose combination of saxagliptin and dapagliflozin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus:- to improve glycaemic control when metformin and/or sulphonylurea (su) and one of the monocomponents of qtern do not provide adequate glycaemic control,- when already being treated with the free combination of dapagliflozin and saxagliptin.
qtern tablet
astrazeneca canada inc - saxagliptin (saxagliptin hydrochloride); dapagliflozin (dapagliflozin propanediol monohydrate) - tablet - 5mg; 5mg - saxagliptin (saxagliptin hydrochloride) 5mg; dapagliflozin (dapagliflozin propanediol monohydrate) 5mg - dipeptidyl peptidase-4 (dpp-4) inhibitors
qtern tablet
astrazeneca canada inc - saxagliptin (saxagliptin hydrochloride); dapagliflozin (dapagliflozin propanediol monohydrate) - tablet - 5mg; 10mg - saxagliptin (saxagliptin hydrochloride) 5mg; dapagliflozin (dapagliflozin propanediol monohydrate) 10mg - dipeptidyl peptidase-4 (dpp-4) inhibitors